Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

Technology Scientific & Technical Instruments
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair... see more

Recent & Breaking News (TSXV:RP)

Canadian Investment Regulatory Organization Trade Resumption - RP

Canada NewsWire October 21, 2024

Canadian Investment Regulatory Organization Trading Halt - RP

Canada NewsWire May 8, 2024

TSX Venture Exchange Stock Maintenance Bulletins

Canada NewsWire November 28, 2023

RepliCel Provides Corporate Update

Accesswire November 28, 2022

RepliCel (TSXV:RP) extends warrant expiry

Caroline Egan  September 16, 2022

RepliCel Announces Material Patent Milestones in Key Markets

Accesswire August 4, 2022

DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections

Accesswire August 2, 2022

RepliCel's Manufacturing Inspected by Japan's PMDA

Accesswire July 28, 2022

CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing

Accesswire July 26, 2022

Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing

Accesswire July 26, 2022

RepliCel Announces Material Patent Milestones

Accesswire January 10, 2022

RepliCel Closed Final Tranche of Strategic Investment Commitment

Accesswire December 21, 2021

RepliCel Terminates License Agreement with Shiseido

Accesswire December 21, 2021

RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing

Accesswire November 11, 2021

RepliCel's Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team

Accesswire November 9, 2021

RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line

Accesswire October 28, 2021

RepliCel Announces Dermal Injector Update

Accesswire October 27, 2021

RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy

Accesswire October 18, 2021

RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor

Accesswire October 12, 2021

RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents

Accesswire September 16, 2021